The Pharma Data

AUGUST 15, 2021

Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses. Although the first vaccines to receive Emergency Use Authorization by the U.S.

Protein 52

Protein Vaccination Vaccine Antibody 52

Pharmaceutical Technology

JUNE 1, 2023

Neumifil consists of an engineered carbohydrate-binding module domain of a Streptococcus pneumoniae protein. The platform is derived from bacterial glycosidases and is researched for potential prophylactic use against respiratory viruses such as influenza. The company dosed the first patient for this study in August 2022. million ($4.75

In-Vitro 130

In-Vitro Engineer Protein Vaccination 130

Drug Discovery World

OCTOBER 27, 2023

Organ-chips combine cell culture with microfluidics to emulate the biological forces of different organ tissues and/or disease states, allowing pharmaceutical researchers to determine a drug candidates’ efficacy and toxicity ahead of clinical trials. Could organ-chips replace other research methods? Not yet, according to Ewart.

Research 72

Research Gene Therapy In-Vivo In-Vitro 72

Drug Discovery World

SEPTEMBER 1, 2022

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. .

Antibody 52

Antibody In-Vitro Development Recombinant Antibody 52

Drug Discovery World

MAY 25, 2023

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. Introduction to the CRUK Beatson Institute The first speaker was Professor Owen Sansom, Director of the Cancer Research UK Beatson Institute, who gave two presentations.

Research 52

Research Drugs In-Vitro Insulin 52

Drug Discovery World

OCTOBER 30, 2023

GeNeuro and Verily will work together to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein (W-ENV) in SARS-CoV-2 infection. Verily will provide high-resolution multi-omic data generated from Covid-19 patient samples using its immune mapping platform, along with high-powered data analysis. “We

In-Vitro 52

In-Vitro Protein Medicine Drugs 52

Pfizer

JANUARY 27, 2023

Pfizer Responds to Research Claims carterda Fri, 01/27/2023 - 19:48 Pfizer Responds to Research Claims Friday, January 27, 2023 - 08:00pm Share New York, N.Y., In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. and around the world.

Research 112

Research Vaccination Vaccine Drugs 112

Drug Discovery World

AUGUST 9, 2022

Based in Dundee, Cypex manufactures recombinant xenobiotic metabolizing enzymes with its product portfolio covering a wide range of proteins involved in drug metabolism. . This technology enables the expression of human drug-metabolizing enzymes in bacteria, without requiring large modifications to the proteins.? .

In-Vitro 52

In-Vitro Protein Production Bacteria 52

Drug Discovery World

OCTOBER 21, 2022

Proteomics, the study of proteins in the human body, has emerged as a promising field in medicine, particularly for its potential to identify subtypes of cancers and match patients with the most appropriate treatment strategy. The results of this study were published in the Journal of Proteome Research by the American Chemical Society.

In-Vitro 52

In-Vitro Protein Medicine Research 52

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Etienne De Braekeleer, Senior Research Scientist, AstraZeneca.

In-Vitro 52

In-Vitro Engineer Scientist Gene Therapy 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Innovation S-curve for artificial Intelligence in the pharmaceutical industry In-silico drug discovery is a key innovation area in artificial Intelligence Drug research starts with the discovery stage that involves in vivo and in vitro models to shortlist lead drug compounds.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

Roots Analysis

AUGUST 7, 2023

On the other hand, cell free system / cell free expression system are ­in-vitro platforms that harness the transcription and translation machinery of living cells, in the form of cell lysates, to synthesize various types of biologics, particularly proteins. Interestingly, most of these kits are used for cell-free protein expression.

Marketing 52

Marketing Protein In-Vitro Production 52

Drug Discovery World

MARCH 26, 2024

Additional approaches, such as profiling of RNA and proteins, and the use of artificial intelligence (AI), could be key to providing a more comprehensive picture of a patient’s tumour and enable the use of optimised treatments. MT: Why was STORM attending the conference? We were there to present the latest findings from our research.

RNA 64

RNA In-Vivo In-Vitro DNA 64

XTalks

SEPTEMBER 30, 2020

While it remains unclear why some people become more gravely ill than others when infected with the SARS-CoV-2 virus that causes COVID-19, researchers have found that an immune deficiency may be part of it. Two recent studies have shown that individuals who lack an important immune factor may have reduced ability to fight the virus.

Antibody 135

Antibody Genetics Research In-Vitro 135

Roots Analysis

AUGUST 15, 2023

Overview of Cell Free Systems Cell-free systems are ­in-vitro platforms which allow occurrence of biochemical reactions in the absence of living cells. Additionally, these types of cell free systems do not contain proteases and nucleases as crude cell lysates, which further helps in improving the production of many proteins.

Protein 52

Protein In-Vitro Production Reagent 52

Drug Discovery World

JUNE 27, 2023

Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area. We look forward to continuing our productive collaboration with our colleagues at IRBM in this compelling area of research.”

In-Vivo 52

In-Vivo In-Vitro Engineer Protein 52

Drug Discovery World

AUGUST 3, 2023

Sygnature Discovery has announced the acquisition of Canada-based contract research organisation NuChem Sciences. Founded in 2011, the company delivers discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology.

In-Vivo 52

In-Vivo In-Vitro Protein Marketing 52

Drug Discovery World

APRIL 21, 2023

Purple Biotech shared the new results at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Florida, US. The study was led by researchers at The University of Texas MD Anderson Cancer Center. The study was led by researchers at The University of Texas MD Anderson Cancer Center.

Drugs 98

Drugs In-Vivo In-Vitro Protein 98

Camargo

NOVEMBER 29, 2021

Recombinant therapeutic proteins. Fusion proteins. They may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.

Development 180

Development Protein Production Hormones 180

The Pharma Data

MARCH 31, 2023

The researchers said the AI tool, dubbed CLEAN, outperforms the leading state-of-the-art tools in accuracy, reliability and sensitivity. Better understanding of enzymes and their functions would be a boon for research in genomics, chemistry, industrial materials, medicine, pharmaceuticals and more.

Protein 40

Protein Genome Genomics Engineer 40

Drug Discovery World

JANUARY 17, 2024

Researchers in Japan have revealed the key underlying mechanisms in muscle atrophy, paving the way towards potential new treatments. The research team conducted experiments involving ‘Mitofusin2’ (MFN2), a protein that is necessary for mitochondria tethering in MAMs. The results were consistent with the in vitro experiments.

In-Vitro 52

In-Vitro Regulation Protein Gene 52

Drug Discovery World

JANUARY 23, 2023

Ubiquigent is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a (de)ubiquitylation (DUB) implicated in neurodegenerative, renal, and cardiovascular diseases. Overseen by Professor Helen Walden, UoG, and Dr Mehmet Gundogdu, Principal Scientist at Ubiquigent, the project aims to combine biochemistry, (..)

In-Vitro 52

In-Vitro Protein Regulation Scientist 52

Drug Discovery World

DECEMBER 13, 2022

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . The genetic anomaly blocks the chemical glycosylation of a biologically important protein. The goal of our research was to find a cure for this intractable disease.

RNA 52

RNA Genetics Gene In-Vitro 52

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are small because they are essentially only the tips of the heavy chain protein arms of a human IgG Y-shaped antibody.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

pharmaphorum

JANUARY 22, 2021

According to the US biopharma company, genetic analyses of publicly available sequences for the new variants of SARS-CoV-2 suggest the mutations in the viral spike protein that have made them more transmissible shouldn’t affect the way Veklury (remdesivir) works. The UK strain – known as B.1.1.7

In-Vitro 140

In-Vitro RNA Licensing Licensing 140

XTalks

JULY 28, 2020

Now, results from a new study conducted by researchers at the UC San Francisco (UCSF) School of Pharmacy and the Novartis Institutes for BioMedical Research (NIBR), have challenged drugmakers’ understanding of the effects of excipients. But just how inert are these excipients?

Protein 103

Protein Drugs In-Vitro Scientist 103

Drug Discovery World

JANUARY 23, 2023

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Drug Discovery World

MARCH 8, 2023

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2. Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumours.

Trials 52

Trials In-Vivo In-Vitro Antibody 52

The Pharma Data

FEBRUARY 25, 2022

Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. ” The findings published today (Feb. 25) in the journal Communications Biology. .

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

XTalks

APRIL 6, 2022

Lung cancer is the most common cancer in men and the third most common cancer in women, according to global lung cancer statistics by the World Cancer Research Fund. The researchers observed lead times of approximately 200 days from the detection of ctDNA to cancer recurrence. Photo source: Inivata.

DNA 105

DNA In-Vitro Doctors Doctor 105

XTalks

MARCH 6, 2024

Brain Awareness Week 2024 , taking place March 11 to 17 this year, is a global campaign that aims to demystify the complexities of the human brain and promote the significance of neuroscientific research. The week-long celebration is also a call to action for increased support and funding for neurological and psychological research.

FDA Approval 69

FDA Approval In-Vitro Research Marketing 69

XTalks

JANUARY 27, 2021

The company used in vitro neutralization antibody studies to evaluate the activity of Moderna’s vaccine-generated antibodies in human sera against several variants of the novel coronavirus, including the B.1.1.7 The in vitro study evaluated the ability of mRNA-1273-generated antibodies to neutralize the new SARS-CoV-2 variants.

Vaccination 52

Vaccination Vaccine In-Vitro Protein 52

Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD. Optimer binders are engineered to overcome these problems.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

XTalks

JUNE 30, 2023

Sartorius is a globally recognized player in the diagnostics industry, providing a variety of solutions for in vitro diagnostics kit (IVD) manufacturers. “By working with customers from the initial research stage through to the development stage and finally the production stage, Sartorius can address and remove any issues. .

In-Vitro 52

In-Vitro Manufacturing Production Antibody 52

The Pharma Data

MAY 31, 2022

Jude Children’s Research Hospital. About Evrysdi® (risdiplam) Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Evrysdi is now approved in the US to treat SMA in children and adults of all ages.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. What is Flow Cytometry?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

XTalks

MAY 12, 2022

This diagnostic assay works on the principle of in vitro nucleic acid amplification using real-time transcription-mediated amplification (TMA) technology. The Aptima CMV Quant Assay helps to detect changes in the viral load of the transplant patient to understand the response of the individual to anti-CMV treatment.

In-Vitro 52

In-Vitro DNA Development Genome 52